TheraRadar
Data updated: Jun 17, 2026

ETOMIDATE

Other Approved 1996-11-04

Etomidate Injection is indicated by intravenous injection for the induction of general anesthesia. When considering use of Etomidate Injection, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY ) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS ).

Source: FDA Label • AVET LIFESCIENCES
11
Indications
--
Phase 3 Trials
29
Years on Market

Details

Status
Discontinued
First Approved
1996-11-04
Routes
INJECTION
Dosage Forms
INJECTABLE

ETOMIDATE Approval History

1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
21 FDA actions from 1996 to 2023
Aug 2023 SUPPL
Label · Labeling
Dec 2020 ORIGINAL
Update
Jul 2020 SUPPL
Label · Labeling

What ETOMIDATE Treats

11 FDA approvals

Originally approved for its first indication in 1996 . Covers 11 distinct patient populations.

  • Other (11)
📋

Clinical Trial Registry

15 trials
Trial Sponsor ID Phase Status Title
NCT05277896 RSI results posted 210500 K23HL153584, BPS-2022C3-30021 Ph 4 completed Randomized Trial of Sedative Choice for Intubation
NCT06664138 DKUH 2023-02-005-002 Ph 4 completed Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment
NCT05223907 ytmz Ph 4 completed Safety and Efficacy of Maintenance of Etomidate in General Anesthesia
NCT06068764 ETOPRO HHC-2023-0114 Ph 4 recruiting Etomidate Versus Propofol in CABG Surgery
NCT02822144 GASS 35RC15_8957 2016-000795-25 Ph 3 completed General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke
NCT02643381 EvK results posted 022015-023 Ph 4 completed Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial
NCT03545503 Ket-RSI results posted 1712-4 Ph 4 completed Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation
NCT02105415 KEEP PACE results posted 13-000506 Ph 2, Ph 3 completed Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial
NCT01823328 results posted HSR 13-3601 Ph 4 completed Ketamine Versus Etomidate for Rapid Sequence Intubation
NCT02500225 Ulku 1 Ph 4 completed Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy
NCT02027311 results posted ETOMI-1 Ph 4 completed Etomidate vs. Midazolam for Sedation During ERCP
NCT02186990 Odu-2 Ph 4 completed Comparison of Etomidate, Propofol and Etomidate-propofol Combination in Terms of Effects on Haemodynamic Response to Intubation
NCT01495949 Si559/2011 Ph 4 completed The Cortisol Levels During Cardiac Surgery. The Comparison Between Etomidate and Thiopentone
NCT01792037 26177 Ph 4 completed Single Dose of Etomidate and Adrenal Cortex
NCT01248234 2010-0097 Ph 3 withdrawn Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ETOMIDATE FDA Label Details

Indications & Usage

Etomidate Injection is indicated by intravenous injection for the induction of general anesthesia. When considering use of Etomidate Injection, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY ) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS ). Intravenous Etomidate Injection is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization.

Looking for the branded version?

AMIDATE

Full clinical data, patents, trials, and competitive landscape for etomidate.

See AMIDATE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.